- Home
- SCNX vs RLYB Comparison
SCNX vs RLYB Comparison
Compare SCNX & RLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SCNX | RLYB |
|---|---|---|
| Founded | 2010 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Pharmaceuticals | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.8M | 24.1M |
| IPO Year | 2020 | 2021 |
Fundamental Metrics
Financial Performance| Metric | SCNX | RLYB |
|---|---|---|
| Price | $0.55 | $0.77 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 1.8M | 177.2K |
| Earning Date | 11-13-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $653,391.00 | ★ $674,000.00 |
| Revenue This Year | N/A | $17.61 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 207.88 | 12.71 |
| 52 Week Low | $0.46 | $0.22 |
| 52 Week High | $8.19 | $1.20 |
Technical Indicators
Market Signals| Indicator | SCNX | RLYB |
|---|---|---|
| Relative Strength Index (RSI) | 42.10 | 67.98 |
| Support Level | $0.60 | $0.72 |
| Resistance Level | $0.75 | $0.80 |
| Average True Range (ATR) | 0.05 | 0.04 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 8.45 | 84.86 |
Price Performance
Historical ComparisonAbout SCNX Scienture Holdings Inc.
Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on providing value to patients and caregivers by offering novel specialty products to satisfy unmet market needs and optimize the prescription journey and patient engagement in the U.S.
About RLYB Rallybio Corporation
Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. The programs of the company are for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.